Acute toxicities of concurrent chemoradiation with 5-fluorouracil versus capecitabine in locally advanced rectal cancer: The Preliminary results of multicenter randomized control trial
Keywords:
capecitabine, concurrent chemoradiation, rectal cancer, toxicity, 5-FUAbstract
Purpose: To compare the acute toxicities of concurrent chemoradiation (CCRT) with infusion 5-fluorouracil (5-FU) versus capecitabine in patients with locally advanced rectal cancer. Materials and Methods: Between January 2015 and October 2015, 48 locally advanced rectal cancer patients from 7 radiotherapy centers in Thailand were randomized into 2 groups. The first group received infusion 5-FU chemotherapy (1,000 mg/m2 days 1-5 and 29-33) during the course of radiation treatment while the other group received oral capecitabine (825 mg/m2, twice daily, 5 days/week). The dose of whole pelvic radiation was 45-50.4 Gy. The acute toxicities during the course of treatment were recorded and compared. Result: Forty-eight locally advanced rectal cancer patients were enrolled in the study, 21 patients were in 5-FU arm and 27 were in capecitabine arm. 47.9% were male and 52.1% were female with a median age of 59 years. Twenty- four patients were treated with preoperative CCRT and 24 patients with postoperative CCRT. No grade 3 or 4 dermatitis and genitourinary toxicities were observed. There were 83.3% of all patients developed diarrhea; 90.4% were in 5-FU arm and 77.8% were in capecitabine arm (p= 0.215). Two patients in 5-FU arm had grade 3 diarrhea but none in capecitabine arm. Grade 1 or 2 hand-foot syndrome developed in capecitabine arm more than 5-FU arm, 22.2% versus 9.6% (p= 0.359). The incidence of grade 1 or 2 anemia was 23.8% and 11.1% in 5-FU and capecitabine arm, respectively (p=0.463). No grade 3 or more anemia and thrombocytopenia were observed. Three patients in 5-FU arm had Grade 3 or 4 leucopenia (14.3%), all of these developed febrile neutropenia, whereas none was observed in capecitabine arm. No treatment related death occurred in this study. Conclusion: This preliminary report showed that the acute toxicities of CCRT with capecitabine in locally advanced rectal cancer are comparable to the standard infusion 5-FU.
References
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-33.
O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S et al. Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04. J Clin Oncol 2014; 32(18): 1927-34.
Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, noninferiority, phase 3 trial. Lancet Oncol 2012; 13: 579–88.
O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG et al Improving adjuvant therapy for rectal cancer by combining protracted- infusion 5-FU with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR et al .Tumor down- staging and sphincter preservation with preoperative chemo- radiation in locally advanced rectal cancer: the M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44:1027.
Myerson RJ, Valentini V, Birnbaum EH, Cellini N, Coco C, Fleshman JW et al. A phase I/II trial of threedimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys 2001; 50: 1299–1308.
Mehta VK, Poen J, Ford J, Edelstein PS, Vierra M, Bastidas AJ, et al. Radiotherapy, concomitant protractedvenous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum 2001; 44: 52-8.
Dunst J, Reese T, Debus J, Hoelscher T, Budach W, Rudat V et al. Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer. Proc Am Soc Clin Oncol 2004; 23:260.
Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54: 403–408.
Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005; 63(2): 346–53.
De PA, Chiara S, Luppi G, Friso ML, Beretta GD, Del Prete S et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006; 17(2): 246–51.
Craven I, Crellin A, Cooper R, Melcher A, Byrne P, Sebag- Montefiore D. Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer 2007; 97(10): 1333–7.
Dupuis O, Vie B, Lledo G, Hennequin C, Noirclerc M, Bennamoun M. Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study. Oncology 2007; 4: 169–76.
Ramani VS, Sun MA, Montazeri A, Wong H. Preoperative chemoradiotherapy for rectal cancer: A comparison between intravenous 5-fluorouracil and oral capecitabine. Colorectal Dis 2010; 12(suppl2): 37-46.
Downloads
Published
How to Cite
Issue
Section
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
